|14th January 2020
In the 20th century, research, technology and new novel treatments have enabled us to increase the average lifespan by 25 years, but our healthspan has not increased accordingly. We live longer, but not necessarily better – unfortunately, our quality of life has not improved throughout these added years. This is in part due to the explosive, bordering on unmanageable, increase in chronic diseases, such as cardiovascular disease, diabetes, Alzheimer’s disease, obesity and asthma.
Often these conditions are not experienced in isolation, resulting in many patients managing two or more comorbidities, leading to complex health problems that are more difficult to monitor and manage.
The World Health Organisation reports that by 2020 chronic diseases will account for three-quarters of all deaths worldwide and will reduce the quality of life for patients and their caregivers. With the average cost of managing comorbid chronic patients in the UK estimated to be eight times that of a relatively healthy patient, the economic impact of these illnesses on healthcare systems is immense.
To solve this problem, our systems must be more efficient and more effective in the management and prevention of chronic diseases.
Digital therapeutics, such as smartphone apps and wearable technology, can be used to relieve some of the pressure. They can be used in a multitude of ways to support the effective delivery of healthcare.
This includes monitoring, motivating, changing behaviour, facilitating communication, and helping to manage processes, all while collecting valuable data. When done well, these tools can facilitate more meaningful interactions between patients and healthcare professionals.
|27th August 2020
Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?
|28th July 2020
At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global response to the virus and to ensure we were best positioned to serve our clients during this challenging time. She shares the key learnings and why understanding the epidemiology of the disease is integral for fighting it.
|14th July 2020
Blue Latitude Health, and our parent company Fishawack Health, have developed exclusive intellectual property, processes and tools to ensure you’re engaging customers in the right way. View our service one-pagers below to find out how we can help solve your challenges whether you’re in a medical, brand, portfolio or an above brand role.